Article in "transkript": 10 minutes make all the difference
We are happy to share the “transkript” article (German), where our CEO Prof. Dr. Juhl discusses how the first 10 minutes can make a crucial difference in precision oncology. He emphasizes the importance of high-quality tumor samples, the role of multi-omics data, and our commitment to identifying novel targets to improve the success rates of cancer therapies.
The First 10 Minutes: Why rapid tissue sample processing is essential for understanding the molecular reality of cancer
Developing effective therapies for increasingly specific patient cohorts is the core aim of precision oncology. Despite medical advancements, many new drugs fail during development due to the lack of therapeutic targets identified early for specific tumor types. The integrity of underlying tumor samples is key. Research shows that limiting ischemia time to under 10-12 minutes significantly impacts target detectability.
Our CEO and Founder Hartmut Juhl discusses in this article how optimized tumor collection processes and high-quality multi-omics data can enhance the identification of novel, disease-relevant targets, ultimately increasing the success rates of preclinical and clinical research.